Live News EQUITY FLASH L impact Nov 18, 2026, 11:30 AM UTC Stifel upgrades Tandem Diabetes Care to Buy, raises target to $26 Stifel raised its rating from Hold to Buy and its target price from $22 to $26. TNDM SquawkNews Desk